371
Participants
Start Date
October 21, 2019
Primary Completion Date
December 31, 2026
Study Completion Date
March 31, 2027
Damoctocog alfa pegol (Jivi, Bay94-9027)
Follow clinical practice. BAY94-9027 is a B-domain-deleted recombinant factor VIII (rFVIII) product site-specifically conjugated to a single (dual 30-kDa branched) 60-kDa polyethylene glycol (PEG) molecule. BAY 94-9027 is intended for prophylaxis and treatment of bleeds in patients with hemophilia A aged ≥12 years, with a narrow, predictable weekly dose that allows for the treatment regimen to be tailored to individual patient needs.
Georgetown University, Washington D.C.
East Carolina University - Brody School of Medicine, Greenville
South Alabama Medical Science Foundation, Mobile
Regents of University of Minnesota, Minneapolis
Tulane University, New Orleans
University of Colorado Hemophilia and Thrombosis Center, Aurora
Banner MD Anderson Cancer Center, Phoenix
Orthopaedic Hospital DBA Orthopaedic Institute for Children, Los Angeles
The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders, Orange
University California Davis, Davis
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Many locations, Multiple Locations
Lead Sponsor
Bayer
INDUSTRY